LSTA Earnings Prediction
The chart below shows how LSTA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LSTA sees a +4.35% change in stock price 10 days leading up to the earnings, and a +1.69% change 10 days following the report. On the earnings day itself, the stock moves by +1.45%. This data can give you a slight idea of what to expect for the next quarter's release.
LSTA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.59
-9.23%
-3.28%
No Data Available
LSTA Earnings Analysis
Lisata Therapeutics, Inc. Common Stock Corporation (LSTA.O) Earnings Conference Call
Positive
Operating Expenses Decrease: Operating expenses totaled $5.3 million compared to $6 million for the same period last year, representing a decrease of $0.6 million, or 10.5%.
R&D Expense Decrease: Research and development expenses were approximately $2.5 million for the three months ended September 30, 2024, compared to $3.4 million for the same period last year, representing a decrease of $0.8 million, or 24.8%.
Cash and Marketable Securities: As of September 30, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $35.9 million.
ASCEND Trial Enrollment Success: The ASCEND trial enrolled 158 patients over the course of about 1.5 years, which was a pretty good enrollment rate considering it was done across about 20 sites in Australia and New Zealand.
Peptide Therapy for Endometriosis: The company has initiated preclinical investigation of certain peptides as a potential therapeutic agent outside of oncology in the treatment of endometriosis, a disease which affects hundreds of millions of women worldwide.
Negative
Operating Expenses Decrease: Operating expenses totaled $5.3 million compared to $6 million for the three months ended September 30, 2023, representing a decrease of $0.6 million, or 10.5%.
R&D Expense Decrease: Research and development expenses were approximately $2.5 million for the three months ended September 30, 2024, compared to $3.4 million for the three months ended September 30, 2023, representing a decrease of $0.8 million, or 24.8%.
Net Loss Comparison: Overall, net losses were $4.9 million for the three months ended September 30, 2024, compared to $5.3 million for the three months ended September 30, 2023.
Projected Capital Funding: The company believes that its projected capital will fund its current proposed operations into early 2026, encompassing anticipated data milestones from all its ongoing and planned clinical trials.
Solid Tumors and Patient Outcomes: Despite advances in cancer therapy, many solid tumors are still associated with poor patient outcomes.
LSTA FAQs
How does LSTA typically perform around its earnings report dates?
Is Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LSTA Earning Call Sentiment
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LSTA.O
0%Positive
The earnings call summary presents several challenges: clinical trial risks, market valuation issues, competitive pressures, and economic factors. Despite reduced expenses and a decrease in net losses, the frustration with share price and market valuation indicates potential negative investor sentiment. The Q&A section highlights slow trial progress and management's lack of specific answers, further adding to concerns. Considering these factors, along with the absence of positive catalysts like a new partnership or raised guidance, the overall sentiment leans negative, predicting a stock price decline of -2% to -8%.
